Editor of Patient Care Online.
FDA Approves Second Naloxone Hydrochloride Nasal Spray for OTC, Nonprescription Use
RiVive™ nasal spray is the second nonprescription naloxone product approved by the FDA for the emergency treatment of opioid overdose.
Daily Dose: Preoperative HIIT and Cardiorespiratory Health Among Adults Undergoing Major Surgery
Your daily dose of clinical news you may have missed.
Early Signs of Atherosclerosis Found in Young Tobacco and E-Cigarette Users
Young adults who smoke tobacco cigarettes or vape showed early signals of atherosclerosis compared with nonsmokers in a small, cross-sectional study.
Daily Dose: The BMI vs Body Fat Debate
New Research Suggests Preoperative High-intensity Interval Training is Beneficial for Cardiorespiratory Health
Findings from meta-analysis showed preoperative high-intensity interval training was associated with improvements in exercise capacity and a reduction in postoperative complications.
Daily Dose: Association of Racial Discrimination with Adiposity in Children
Daily Dose: T2D Raises Risk for Hepatic Decompensation, Hepatocellular Carcinoma in Patients with NAFLD
FDA Approves First Over-the-Counter Daily Oral Contraceptive Pill
The US FDA approved norgestrel as the first daily oral contraceptive to be available over the counter, without a prescription.
Daily Dose: Trends in Body Weight Perception Among Adolescents
Racial Discrimination may be Risk Factor for Obesity in Children, Suggests New Research
Children and adolescents who reported facing more racial discrimination had a higher BMI and waist circumference, according to new data.
Daily Dose: Opioid Use for Low Back Pain and Neck Pain
More Adolescents Worldwide Experience Body Weight Misperceptions, According to New Study
Underestimation of weight status increased while overestimation decreased during the last 2 decades, according to results from a study of over 745 000 adolescents.
Daily Dose: Association of Population Wellbeing with Cardiovascular Outcomes
Expert to Primary Care: Use these "ABCs" to Manage Obesity and T2D
The importance of avoiding judgement, monitoring behavior, and cardiovascular risk prevention in primary care are discussed, here.
Daily Dose: Vitamin D Supplementation and Major Cardiovascular Events in Older Adults
Statins Appear Beneficial for CV Outcomes in Primary Prevention Patients with HTN without CVD or Diabetes
In a study of over 26 000 participants, statin use was associated with reduced risk for all-cause and CV mortality compared to placebo.
Daily Dose: Loneliness and CVD Risk in Patients with Diabetes
Frequent Opioid Use for Low Back Pain, Neck Pain Called into Question in New Study
Results showed that the use of opioid analgesics did not confer any benefits for adults with acute low back pain or neck pain compared to placebo.
Daily Dose: Childhood Glycemic Measures as Predictors of Diabetes-Related Complications
Treating Obesity & T2D: Experts Say Simultaneous, Early Intervention is Key
Early intervention is crucial to help prevent complications in patients with obesity and type 2 diabetes. Two experts explain more, here.
Monthly Vitamin D Supplementation May Lower the Risk of Major CV Events in Older Adults
Vitamin D supplementation may reduce the incidence of major cardiovascular events in older adults, suggests new research.
Daily Dose: Pegozafermin in Patients with NASH
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Daily Dose: High-Dose Oral Semaglutide May be Beneficial for T2D Management
Glycemic Screening in Childhood May Predict Diabetes-Related Complications, According to New Data
ADA 2023: Findings from a new study show that higher levels of glycemia in childhood are associated with future microvascular complications, such as nephropathy and retinopathy.
Daily Dose: HF, CV Benefit of SGLT-2 Inhibition Consistent in T2D, CDK, HF
Health Inequities in Persons with Obesity & Type 2 Diabetes Exacerbated During COVID-19 Pandemic
Listen to 2 obesity experts discuss the impact of the COVID-19 pandemic on obesity-related type 2 diabetes.
Daily Dose: Bempedoic Acid Reduces Risk for MACE in Primary Prevention Population
New Data Suggest Higher Doses of Oral Semaglutide Beneficial for Management of Type 2 Diabetes
ADA 2023. Results from PIONEER PLUS trial showed oral semaglutide 25 mg and 50 mg were superior than 14 mg in reducing HbA1c and body weight in adults with T2D.
Daily Dose: Novel Drug Therapy for Obesity Shown Effective Up to 46 Weeks